Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections
The emergence of multi-drug resistant (MDR) bacteria is recognised today as one of the greatest challenges to public health. As traditional antimicrobials are becoming ineffective and research into new antibiotics is diminishing, a number of alternative treatments for MDR bacteria have been receivin...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/9/1809 |
| id |
doaj-1f61c9516fd4496c9e458b898a8d4042 |
|---|---|
| record_format |
Article |
| spelling |
doaj-1f61c9516fd4496c9e458b898a8d40422021-09-26T01:37:32ZengMDPI AGViruses1999-49152021-09-01131809180910.3390/v13091809Phage Therapy for Multi-Drug Resistant Respiratory Tract InfectionsJoshua J. Iszatt0Alexander N. Larcombe1Hak-Kim Chan2Stephen M. Stick3Luke W. Garratt4Anthony Kicic5Occupation, Environment and Safety, School of Population Health, Curtin University, Perth 6845, AustraliaOccupation, Environment and Safety, School of Population Health, Curtin University, Perth 6845, AustraliaAdvanced Drug Delivery Group, Sydney Pharmacy School, University of Sydney, Camperdown 2006, AustraliaWal-yan Respiratory Research Centre, Telethon Kids Institute, Perth 6009, AustraliaWal-yan Respiratory Research Centre, Telethon Kids Institute, Perth 6009, AustraliaOccupation, Environment and Safety, School of Population Health, Curtin University, Perth 6845, AustraliaThe emergence of multi-drug resistant (MDR) bacteria is recognised today as one of the greatest challenges to public health. As traditional antimicrobials are becoming ineffective and research into new antibiotics is diminishing, a number of alternative treatments for MDR bacteria have been receiving greater attention. Bacteriophage therapies are being revisited and present a promising opportunity to reduce the burden of bacterial infection in this post-antibiotic era. This review focuses on the current evidence supporting bacteriophage therapy against prevalent or emerging multi-drug resistant bacterial pathogens in respiratory medicine and the challenges ahead in preclinical data generation. Starting with efforts to improve delivery of bacteriophages to the lung surface, the current developments in animal models for relevant efficacy data on respiratory infections are discussed before finishing with a summary of findings from the select human trials performed to date.https://www.mdpi.com/1999-4915/13/9/1809multi-drug resistancebacteriophagerespiratoryinfectious disease |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Joshua J. Iszatt Alexander N. Larcombe Hak-Kim Chan Stephen M. Stick Luke W. Garratt Anthony Kicic |
| spellingShingle |
Joshua J. Iszatt Alexander N. Larcombe Hak-Kim Chan Stephen M. Stick Luke W. Garratt Anthony Kicic Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections Viruses multi-drug resistance bacteriophage respiratory infectious disease |
| author_facet |
Joshua J. Iszatt Alexander N. Larcombe Hak-Kim Chan Stephen M. Stick Luke W. Garratt Anthony Kicic |
| author_sort |
Joshua J. Iszatt |
| title |
Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections |
| title_short |
Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections |
| title_full |
Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections |
| title_fullStr |
Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections |
| title_full_unstemmed |
Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections |
| title_sort |
phage therapy for multi-drug resistant respiratory tract infections |
| publisher |
MDPI AG |
| series |
Viruses |
| issn |
1999-4915 |
| publishDate |
2021-09-01 |
| description |
The emergence of multi-drug resistant (MDR) bacteria is recognised today as one of the greatest challenges to public health. As traditional antimicrobials are becoming ineffective and research into new antibiotics is diminishing, a number of alternative treatments for MDR bacteria have been receiving greater attention. Bacteriophage therapies are being revisited and present a promising opportunity to reduce the burden of bacterial infection in this post-antibiotic era. This review focuses on the current evidence supporting bacteriophage therapy against prevalent or emerging multi-drug resistant bacterial pathogens in respiratory medicine and the challenges ahead in preclinical data generation. Starting with efforts to improve delivery of bacteriophages to the lung surface, the current developments in animal models for relevant efficacy data on respiratory infections are discussed before finishing with a summary of findings from the select human trials performed to date. |
| topic |
multi-drug resistance bacteriophage respiratory infectious disease |
| url |
https://www.mdpi.com/1999-4915/13/9/1809 |
| work_keys_str_mv |
AT joshuajiszatt phagetherapyformultidrugresistantrespiratorytractinfections AT alexandernlarcombe phagetherapyformultidrugresistantrespiratorytractinfections AT hakkimchan phagetherapyformultidrugresistantrespiratorytractinfections AT stephenmstick phagetherapyformultidrugresistantrespiratorytractinfections AT lukewgarratt phagetherapyformultidrugresistantrespiratorytractinfections AT anthonykicic phagetherapyformultidrugresistantrespiratorytractinfections |
| _version_ |
1716868599684005888 |